Compare PMT & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | SGP |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 799.4M |
| IPO Year | 2009 | 2026 |
| Metric | PMT | SGP |
|---|---|---|
| Price | $7.38 | $24.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $11.11 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 2.0M | 108.2K |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | ★ 21.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $351,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.07 | N/A |
| P/E Ratio | $18.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $17.06 |
| 52 Week High | $13.80 | $30.56 |
| Indicator | PMT | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 22.82 | 43.31 |
| Support Level | N/A | $24.85 |
| Resistance Level | $9.80 | $26.29 |
| Average True Range (ATR) | 0.23 | 1.43 |
| MACD | -0.06 | -0.37 |
| Stochastic Oscillator | 4.18 | 29.19 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.